Logo - springer
Slogan - springer

Medicine - Internal Medicine | Pulmonary Therapy (Editorial Board)

We’re working on a new version of this journal site - preview it now
Pulmonary Therapy

Pulmonary Therapy

ISSN: 2364-1746 (electronic version)

Journal no. 41030



Kai-Michael Beeh, insaf Respiratory Research Institute, Wiesbaden, Germany


Rajiv Dhand, University of Tennessee Graduate School of Medicine, Tennessee, USA

Editorial Board

The Editorial board are responsible for assisting the in-house editorial team by providing final decisions on papers when peer review is conflicting, contributing their own research, suggesting review topics and generally supporting the journal in its development.

Israel Amirav, University of Alberta, Canada
Harm-Jan Bogaard, VU University Amsterdam, The Netherlands
Sinthia Z Bosnic-Anticevich, University of Sydney, Sydney, Australia
Kenneth R Chapman, University of Toronto, Toronto, Canada
Ira M Cheifetz, Duke Children's Hospital, Durham, USA
Timothy Craig, Pennsylvania State University, Pennsylvania, USA
Adnan Custovic, Imperial College, London, UK
Keertan Dheda, University of Cape Town, Cape Town, South Africa
Robert J Downey, Memorial Sloan Kettering Cancer Center, New York, USA
Marcus Kennedy, Cork University Hospital, Cork, Ireland
Nikos Papadopoulos, Royal Manchester Children's Hospital, Manchester, UK
David Price, Observational and Pragmatic Research Institute, Singapore
Roy Pleasants, Duke University School of Medicine, USA
Raffaele Scala, Donato Hospital, Arezzo, Italy
Dominick Shaw, University of Nottingham, UK
Paolo Spagnolo, University of Padua, Padua, Italy
Wim Timens, University Medical Center Groningen, Groningen, The Netherlands

Advisory Board

The advisory board are primarily responsible for providing peer review comments which helps the in-house editorial team maintain our rapid publication timelines. The advisory board also contribute their own research and reviews.

Mohamed Abdelrahim, Beni Suef University, Beni Suef, Egypt
Sabina Antoniu, University of Medicine and Pharmacy Gr T Popa Iasi, Iasi County, Romania
Elisabeth Bendstrup, Aarhus University, Aarhus, Denmark
Marcus W Butler, St. Vincent's University Hospital, Dublin, Ireland
Gaetano Caramori, Università degli Studi di Messina, Messina, Italy
Nazia Chaudhuri, University Hospital of South Manchester, Manchester, UK
Andrew Churg, University of British Columbia, Vancouver, Canada
Ian Clifton, University of Leeds, UK
Konstantinos Dimopoulos, Imperial College London, London, UK
Ankur Girdhar, Peninsula Regional Medical Center, Salisbury, USA
Nicholas Gross, Stritch-Loyola School of Medicine, Chicago, USA
Jayne Holme, Manchester University NHS Foundation Trust, UK
Gareth Hughes, The University of Manchester, UK
Ahmad Kantar, University Research Ponte San Pietro, Bergamo, Italy
Andrea S. Melani, Universitaria Senese, Siena, Italy
Pierluigi Paggiaro, Università di Pisa, Pisa, Italy
Jordi Rello, Joan XXIII University Hospital, Tarragona, Spain
Meenal Sinha, University of California San Francisco, California, USA
Simon Francis Thomsen, Bispebjerg Hospital, Copenhagen, Denmark
Gema Tirado-Conde, Unidad de Gestión Intercentros de Neumología, Cádiz, Spain
Antoni Xaubet, Hospital Clinic de Barcelona, Barcelona, Spain

For authors and editors

  • Aims and Scope

    Aims and Scope


    Aims and Scope

    Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.

    Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.

    The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.

    Rapid Publication

    The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of pulmonary therapies.

    Personal Service

    The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript.  The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research.

    Enhanced Digital Features

    Pulmonary Therapy offers a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Each paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the content to a wide readership. Articles also have the option to include other enhanced digital features including (but not limited to) slide sets, videos, video abstracts, podcasts, infographics and animations. Adis can create digital features for you, or you can submit your own. All these enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research. For questions relating specifically to these features, please contact adisdigitalfeatures@springer.com.
    Plain Language Summaries

    Articles published in Pulmonary Therapy may be accompanied by plain language summaries to assist in understanding important medical advances. Both the enhanced digital features and plain language summaries can help to reach a broader audience thus supporting the effective dissemination of research.

    Publication Fees

    Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of $4500/ €4000. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Considering the time and effort required for a detailed peer review we also reward our regular reviewers with the opportunity to publish without the Rapid Service Fee (pending peer review) for every three reviews completed per calendar year.  All articles are published open access.

    Peer Review Process

    Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria.

    At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor.


    We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Please follow the link for further information on preprint sharing:


    Pulmonary Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0.


    For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.

  • Submit Online
  • Instructions for Authors (pdf, 1.2 MB)
  • Author Disclosure Form (docx, 45 kB)
  • Compliance with Ethical Policies
  • Copyright Information

    Copyright Information


    Copyright Information

    Open Access Pulmonary Therapy is published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0

    Journal ownership: Springer Healthcare

    Copyright of articles: © The Author(s)

Alerts for this journal


Get the table of contents of every new issue published in Pulmonary Therapy.

Additional information